Comprehensive Cardiovascular and Renal Protection in Patients with Type 2 Diabetes

Type 2 diabetes (T2DM) is one of the main public health care problems worldwide. It is associated with a marked increased risk of developing atherosclerotic vascular disease, heart failure, chronic kidney disease and death. It is essential to act during the early phases of the disease, through the i...

ver descrição completa

Detalhes bibliográficos
Autores: Castro Conde, Almudena, Marzal Martín, Domingo, Campuzano Ruiz, Raquel, Fernández Olmo, Maria Rosa, Morillas Ariño, Carlos, Gómez-Doblas, Juan José|||0000-0002-9020-639X, Górriz, Jose Luis|||0000-0002-1134-9051, Mazón Ramos, Pilar, Garcia-Moll, Xavier|||0000-0001-7837-8378, Soler, María José|||0000-0003-3621-0766, León Jiménez, David|||0000-0003-4343-045X, Arrarte Esteban, Vicente|||0000-0002-7371-910X, Obaya Rebollar, Juan Carlos|||0000-0002-2879-1743, Escobar, Carlos|||0000-0001-5584-4735, Gorgojo Martínez, Juan José|||0000-0002-8679-0968
Formato: artículo
Fecha de publicación:2023
País:España
Recursos:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:301682
Acesso em linha:https://ddd.uab.cat/record/301682
https://dx.doi.org/urn:doi:10.3390/jcm12123925
Access Level:acceso abierto
Palavra-chave:GLP-1 receptor agonists
SGLT2 inhibitors
Cardiovascular
Diabetes
Glycated hemoglobin
Renal
Descrição
Resumo:Type 2 diabetes (T2DM) is one of the main public health care problems worldwide. It is associated with a marked increased risk of developing atherosclerotic vascular disease, heart failure, chronic kidney disease and death. It is essential to act during the early phases of the disease, through the intensification of lifestyle changes and the prescription of those drugs that have been shown to reduce these complications, with the aim not only of achieving an adequate metabolic control, but also a comprehensive vascular risk control. In this consensus document, developed by the different specialists that treat these patients (endocrinologists, primary care physicians, internists, nephrologists and cardiologists), a more appropriate approach in the management of patients with T2DM or its complications is provided. A particular focus is given to the global control of cardiovascular risk factors, the inclusion of weight within the therapeutic objectives, the education of patients, the deprescription of those drugs without cardiovascular benefit, and the inclusion of GLP-1 receptor agonists and SGLT2 inhibitors as cardiovascular protective drugs, at the same level as statins, acetylsalicylic acid, or renin angiotensin system inhibitors.

Registos relacionados